Phase 3 Clinical Trials With Primary Completion Dates in August 2019

This is a list of Phase 3 trials with primary completion dates in August 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2019-08-01 Phase 3 NCT02970292 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
ACST Acasti Pharma, Inc. 2019-08-01 Phase 3 NCT03361501 A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
ALKS Alkermes plc 2019-08-01 Phase 3 NCT02873208 A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
ATNX Athenex, Inc. 2019-08-01 Phase 3 NCT02594371 Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer
CPRX Catalyst Pharmaceuticals, Inc. 2019-08-01 Phase 3 NCT03304054 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
EGRX Eagle Pharmaceuticals, Inc. 2019-08-01 Phase 3 NCT03600376 Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
KPTI Karyopharm Therapeutics Inc. 2019-08-01 Phase 3 NCT03555422 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer.
NTEC Intec Pharma Ltd. 2019-08-01 Phase 3 NCT02605434 A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients
SNY Sanofi 2019-08-01 Phase 3 NCT03510715 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
SNY Sanofi 2019-08-01 Phase 3 NCT03001011 Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
TEVA Teva Pharmaceutical Industries Limited 2019-08-01 Phase 3 NCT03756883 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma